Studies in patients with chronic lymphocytic leukemia (CLL) receiving CART19 have shown that prolonged ibrutinib treatment contributes to decreased expression of T-cell inhibitory molecules (PD-1 and CD200) with reversion of functional status of CAR19 T cells and enhanced in vivo proliferation (83, 84). This evidence concerns the gene CD200 and B-cell chronic lymphocytic leukemia.